S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS.

Study Overview
=================
Brief Summary
-----------------
RATIONALE: Collecting and storing samples of blood and bone marrow from patients with cancer to study in the laboratory may help doctors find better ways to ways to treat the cancer. PURPOSE: The purpose of this study is to collect and store blood and bone marrow samples from patients with multiple myeloma, smoldering myeloma, Waldenstrom's macroglobulinemia, amyloidosis, and monoclonal gammopathy of undetermined significance to be tested in the laboratory.

Detailed Description
-----------------
OBJECTIVES: Maintain and expand tissue repositories of myeloma specimens from uniformly treated Southwest Oncology Group (SWOG) patients with multiple myeloma, smoldering myeloma, Waldenstrom's macroglobulinemia, amyloidosis, or monoclonal gammopathy of undetermined significance. Utilize scientific information generated from intergroup and collaborative studies to assist the SWOG Myeloma Committee in the development of new and more effective treatment regimens for these patients. OUTLINE: Patients receive treatment as directed by the treatment protocols on which they are registered. Specimens of blood and/or marrow are submitted to the Myeloma Repository. The status of the patient (e.g., pre-study, post-remission, or relapse) will be recorded prior to specimen collection. PROJECTED ACCRUAL: Not specified

Official Title
-----------------
S0309, Myeloma Specimen Repository Protocol, Ancillary

Conditions
-----------------
Multiple Myeloma, Smoldering Myeloma, Waldenstrom's Macroglobulinemia, Monoclonal Gammopathy of Undetermined Significance, Amyloidosis

Intervention / Treatment
-----------------
* Other: biologic sample preservation procedure


Participation Criteria
=================
Eligibility Criteria
-----------------
DISEASE CHARACTERISTICS: Diagnosis of 1 of the following: Multiple myeloma Smoldering myeloma Waldenstrom's macroglobulinemia Amyloidosis Monoclonal gammopathy of undetermined significance Must be currently registered on a Southwest Oncology Group-coordinated treatment study (SWOG or Intergroup) Must have pretreatment specimens to submit to this study No cytogenetic samples PATIENT CHARACTERISTICS: Not specified PRIOR CONCURRENT THERAPY: Not specified
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: biologic sample preservation procedure|Blood and 3-4 cc bone marrow aspirate collected at same time (in association with treatment protocols on which patient is registered)|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Maintenance and expansion of tissue repositories of myeloma specimens from uniformly treated SWOG patients with multiple myeloma, smoldering myeloma, Waldenstrom's macroglobulinemia, amyloidosis, or monoclonal gammopathy of undetermined significance |  | 7 years | 
| Development of new and more effective treatment regimens for these patients using scientific information generated from intergroup and collaborative studies |  | 7 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
multiple myeloma, Waldenström macroglobulinemia, monoclonal gammopathy of undetermined significance, primary systemic amyloidosis